NanoVibronix, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US63008J6038
USD
4.09
0.29 (7.63%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About NanoVibronix, Inc. stock-summary
stock-summary
NanoVibronix, Inc.
Pharmaceuticals & Biotechnology
NanoVibronix, Inc. is a medical device company focusing on noninvasive biological response-activating devices that target wound healing and pain therapy. The Company's products include PainShield, WoundShield and UroShield. Its products under development include Renooskin and Endotrachshield. The Company's principal research and development activities are conducted in Israel, through its subsidiary, NanoVibronix (Israel 2003) Ltd. The Company operates in the United States, Europe and India, among others. The PainShield is a disposable patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. The Company's WoundShield system is a patch-based therapeutic ultrasound device that facilitates tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation.
Company Coordinates stock-summary
Company Details
525 Executive Blvd , ELMSFORD NY : 10523-1240
stock-summary
Tel: 1 914 2333004
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (1.07%)

Foreign Institutions

Held by 3 Foreign Institutions (0.11%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Christopher Fashek
Chairman of the Board
Mr. Brian Murphy
Chief Executive Officer, Director
Dr. Harold Jacob
Chief Medical Officer, Director
DR. Martin Goldstein
Director
Michael Ferguson
Independent Director
Mr. Thomas Mika
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
0 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 4 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.05

stock-summary
Return on Equity

-11.15%

stock-summary
Price to Book

0.11